Aktie A2QP0Q LIPIGON PHARMACEUTICALS AB
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Lipigon Pharmaceuticals AB

Aktien

A2QP0Q

SE0015382072

LPGO

Markt geschlossen - Nasdaq Stockholm
Andere Börsenplätze
 17:29:40 17.05.2024 		% 5 Tage % 1. Jan.
0,354 SEK +20,41 % Intraday Chart für Lipigon Pharmaceuticals AB +26,65 % -17,87 %
14.05. Lipigon Pharmaceuticals AB (publ) arbeitet mit der University of Washington an einem Projekt zur Lungenschädigung zusammen CI
14.05. Lipigon arbeitet mit der University of Washington an einem Projekt zur Schädigung der Lunge CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Lipigon Pharmaceuticals AB Collaborates with University of Washington on Lung Damage Project
Lipigon Collaborates with University of Washington on Lung Damage Project
Lipigon Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Lipigon Pharmaceuticals’ Lipisense Gets Swedish Regulators' Nod for Mid-stage Study
The Swedish Medical Products Agency Approves Lipigon's Phase II Study with Lipisense
Lipigon Pharmaceuticals AB Announces Lipisense Progressing to Phase II Trials
Lipigon Pharmaceuticals AB Reports A Statically Confirms reduction of target protein ANGPTL4 after repeate treatment with Lipisense ®
Lipigon Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Lipigon Applies for Clinical Trial Phase II for Lipisense
Lipigon Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Lipigon Pharmaceuticals AB Announces Positive Safety Results and Encouraging Target Engagement Data from the Phase I Lipisense Trial
Lipigon Pharmaceuticals Surges 40% on Lipisense Development, Licensing Deal in China
Lipigon Announces Development and License Agreement with Leaderna Therapeutics Ltd
Lipigon Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2023
Lipigon Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
Lipigon Pharmaceuticals AB Reports Earnings Results for the Full Year Ended December 31, 2022
Lipigon Announces Further Positive Data from Phase I Trial of Lipisense
Lipigon Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Lipigon Pharmaceuticals AB Announces Positive Top-Line Data from Phase I Clinical Study of Lipisense
Lipigon Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QP0Q Aktie
  4. Nachrichten Lipigon Pharmaceuticals AB
  5. Andere Sprachen